Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that regularly issues news about its small molecule programs for cancer and genetic disease. Company updates frequently highlight progress for its lead PI3Kα program, RLY-2608, also referred to as zovegalisib, and the use of its Dynamo® platform to address challenging protein targets.
Investors and followers of RLAY news can expect detailed announcements on clinical trial milestones, including interim and subset analyses from the ReDiscover first-in-human study and the Phase 3 ReDiscover-2 trial in HR+/HER2- breast cancer with PI3Kα mutations. Press releases have described efficacy measures such as progression-free survival and objective response rates, as well as safety and tolerability profiles for zovegalisib or RLY-2608 in combination with agents like fulvestrant and CDK inhibitors.
Relay Therapeutics also issues corporate and financial updates, such as quarterly financial results, cash runway commentary, and changes to its Board of Directors. These items are often accompanied by Form 8-K filings and may include information on research and development spending, general and administrative expenses, and net loss figures, without serving as investment advice.
Additional news items cover participation in healthcare and biotechnology investor conferences, where company management joins fireside chats hosted by firms such as Jefferies, Goldman Sachs, Wells Fargo, Guggenheim and Morgan Stanley. These events provide further context on strategy, the Dynamo platform, and the clinical pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
This news page aggregates such disclosures so readers can follow Relay Therapeutics’ clinical progress, scientific presentations at meetings like ASCO and SABCS, and ongoing corporate developments related to the RLAY stock.
Relay Therapeutics (Nasdaq: RLAY) announced plans to report its Q2 2022 financial results and corporate highlights after market close on August 4, 2022. The company specializes in precision medicine, leveraging its Dynamo™ platform to enhance drug discovery processes, particularly in oncology and genetic disease treatment.
Relay Therapeutics aims to revolutionize drug development through advanced computational and experimental technologies, focusing on previously challenging protein targets.
Relay Therapeutics has announced key developments regarding RLY-4008, following a productive end-of-phase 1 meeting with the FDA. The company plans a single-arm trial for FGFR2-fusion cholangiocarcinoma, potentially facilitating accelerated approval. Interim data revealed a 62% confirmed partial response rate among FGFRi-naïve patients treated with a 70 mg dose. Additionally, Relay introduced three new programs targeting HR+/HER2- breast cancer and confirmed adequate funding to sustain operations through 2025.
Relay Therapeutics, a clinical-stage precision medicine company, has announced that registration is now open for its virtual analyst and investor event scheduled for June 27, 2022. The event will run from 8:00 a.m. to 9:00 a.m. ET and will be accessible via the company’s website. Relay Therapeutics aims to innovate drug discovery through its advanced Dynamo™ platform, targeting oncology and genetic diseases. The company focuses on developing transformative therapies utilizing unique computational and experimental technologies.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:30 a.m. ET and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 5:40 p.m. ET. Both events will be webcast live, accessible via Relay Therapeutics' website, and archived for 30 days post-event. The company focuses on precision medicines, integrating advanced computational and experimental technologies to enhance drug discovery in oncology and genetic disease.
Relay Therapeutics (Nasdaq: RLAY) reported its first quarter 2022 financial results, showing a net loss of $62.0 million or $0.57 per share, up from a net loss of $42.2 million in Q1 2021. As of March 31, 2022, the company held approximately $898 million in cash and equivalents, sufficient to support operations into 2025. Notable achievements include the initiation of the combination arm for RLY-2608 and continued enrollment for RLY-4008 expansion cohorts. The company anticipates releasing initial clinical data for RLY-2608 in H1 2023.
Relay Therapeutics (Nasdaq: RLAY) announced participation in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 3:20 p.m. PT in Las Vegas, NV. The chat will be broadcast live via their website and can be accessed under the Events section. An archived replay will be available for 30 days post-event. Relay Therapeutics focuses on precision medicines, leveraging its Dynamo™ platform for drug discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) will announce its first quarter 2022 financial results and corporate highlights on May 5, 2022, after market close. The company is focused on transforming drug discovery through its innovative Dynamo™ platform, which leverages advanced computational and experimental technologies to target previously difficult-to-drug proteins. Relay Therapeutics aims to pioneer new small molecule therapies primarily for oncology and genetic diseases, potentially impacting patient outcomes significantly.
Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical data for RLY-4008, the first therapy targeting FGFR2, showing approximately 80% of patients with FGFR2-altered tumors achieved tumor size reductions. The company reported a net loss of $67.5 million for Q4 2021, with total cash and investments of $958.1 million as of December 31, 2021, expected to fund operations into at least 2025. Relay also presented preclinical data for RLY-2608, an innovative PI3Kα inhibitor, and outlined significant growth in R&D expenses due to increased clinical activities.
Relay Therapeutics (Nasdaq: RLAY) announced plans to release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. The company specializes in precision medicine, leveraging advanced computational and experimental technologies to enhance drug discovery. Notably, Relay Therapeutics utilizes its Dynamo™ platform to target challenging protein structures, focusing on therapies for oncology and genetic diseases. A teleconference will not be held alongside this press release.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming healthcare conferences. The first is a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 9:30 a.m. ET. Following this, Relay will join a panel discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. Both events will be webcast live, and viewers can access them via the Investors & Media page on Relay's website. Archived replays will be available for 30 days post-event.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
